老年胶质母细胞瘤患者的治疗模式与生存结局
基于美国国家癌症数据库2004—2016年104,456例胶质母细胞瘤患者的数据,分析老年患者治疗选择与生存的关系。老年患者接受放疗、化疗和手术切除的比例均显著低于非老年患者,总生存期平均9.1个月,5年生存率5.3%。多因素分析显示,年龄75—84岁和较低KPS评分与生存恶化相关,而手术切除、放疗和化疗与生存改善相关。
要点
- 老年胶质母细胞瘤患者接受手术、放疗和化疗的比例均显著低于非老年患者。
- 年龄75—84岁和KPS≤70与总生存期缩短独立相关,而手术切除、放疗和化疗与生存改善相关。
- 各治疗方式对生存的改善不受体能状态影响,但需权衡患者个体因素与生活质量。
核心结论
- 在104,456例胶质母细胞瘤患者中,老年患者接受各类治疗的比例均较低,但手术切除、放疗和化疗仍与生存改善相关,且不受体能状态影响。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库2004—2016年诊断为胶质母细胞瘤的104,456例患者,采用单因素和多因素Cox回归分析。
主要发现
- 老年患者接受放疗的比例为61.3%,低于非老年患者的77.8%(P < 0.001)。
- 老年患者接受化疗的比例为47.2%,低于非老年患者的62.9%(P < 0.001)。
- 老年患者接受手术切除的比例为68.3%,低于非老年患者的81.8%(P < 0.001)。
- 总体平均总生存期为9.1个月(标准差10.0),5年生存率为5.3%。
- 多因素分析显示,年龄75—84岁(HR 1.39,95%CI 1.12—1.73,P = 0.003)和KPS 50—70(HR 1.68,95%CI 1.35—2.08,P < 0.001)、KPS ≤40(HR 1.79,95%CI 1.18—2.72,P = 0.006)与总生存期缩短相关;而部分切除(HR 0.52,95%CI 0.38—0.71,P < 0.001)、全切除(HR 0.29,95%CI 0.21—0.41,P < 0.001)、放疗(HR 0.65,95%CI 0.47—0.91,P = 0.012)和化疗(HR 0.65,95%CI 0.48—0.88,P = 0.006)与总生存期改善相关。
临床怎么用
- 对老年胶质母细胞瘤患者,应综合评估年龄、体能状态和生活质量需求,个体化选择手术、放疗和化疗等治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with an increased incidence among the elderly. However, the optimal treatment strategy in elderly patients remains unclear. This study seeks to investigate the effect of patient selection and treatment strategies on survival trends in these patients. METHODS: Patients with diagnosis codes specific for GBM were queried from the National Cancer Database during 2004-2016. Univariate and multivariate Cox regression analysis was performed to investigate outcomes. Survival curves and 5-year survival were also generated based on patient-specific factors. RESULTS: Among 104,456 patients with GBM identified, elderly patients were less likely to receive radiotherapy (61.3% vs. 77.8%; P < 0.001) or chemotherapy (47.2% vs. 62.9%; P < 0.001) or to undergo surgical resection (68.3% vs. 81.8; P < 0.001). Mean overall survival was 9.1 months (standard deviation, 10.0) and 5-year survival was 5.3%. Multivariate analysis showed age 75-84 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 1.12-1.73; P = 0.003) and lower Karnofsky Performance Status (50-70: HR, 1.68, 95% CI, 1.35-2.08, P < 0.001; ≤40: HR, 1.79, 95% CI 1.18-2.72, P = 0.006) were associated with decreased overall survival, whereas surgical resection (subtotal resection: HR, 0.52, 95% CI, 0.38-0.71, P < 0.001; gross total resection: HR, 0.29, 95% CI, 0.21-0.41, P < 0.001), radiotherapy (HR, 0.65; 95% CI, 0.47-0.91; P = 0.012), and chemotherapy (HR, 0.65; 95% CI, 0.48-0.88; P = 0.006) were associated with increased overall survival in elderly patients. CONCLUSIONS: In an analysis of 104,456 patients with GBM, all treatment modalities were found to be used less frequently in elderly patients. Increasing age and poor performance status were associated with worsened survival. Gross total resection was associated with the greatest survival benefit, and chemotherapy and radiotherapy also improved survival outcomes. These treatment options improved outcomes regardless of performance status. Although maximal treatment strategies may improve survival in elderly patients with GBM, these treatment strategies must be balanced against patient-specific factors and quality-of-life concerns.
引用
- Nunna RS, Khalid SI, Patel S, et al. Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. World Neurosurg. 2021. PMID: 33482415. doi:10.1016/j.wneu.2021.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。